Published in Law and Health Weekly, June 12th, 2004
Sales of sumatriptan, a migraine remedy marketed as Imitrex in the U.S. by GlaxoSmithKline, are currently more than $1 billion.
The drug's new formulation utilizes NovaDel's patented lingual spray drug-delivery technology to achieve more rapid onset of therapeutic activity. This is considered a desired benefit for patients suffering from a variety of medically treatable conditions, of which migraine headaches are a prime example.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly